טוען...
Adriamycin inhibits glycolysis through downregulation of key enzymes in Saccharomyces cerevisiae
Adriamycin is a widely used drug for the treatment of various types of cancers, but its clinical application is limited because of irreversible dilated cardiomyopathy. The incidence of cardiomyopathy is a consequence of disrupted energy production, which could be related to the defects in glycogen,...
שמור ב:
| הוצא לאור ב: | 3 Biotech |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer International Publishing
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7778664/ https://ncbi.nlm.nih.gov/pubmed/33442514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13205-020-02530-9 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|